News

Regional and national decision-making can be informed by the online model, called the COVID-19 Pool Tool.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

The study helps to illuminate how spike proteins initiate infections.

Fostemsavir, an HIV-1 attachment inhibitor, is a novel therapeutic option for multidrug-resistant HIV. It represents the first oral agent developed for this indication in over a decade and provides promise for patients with limited remaining treatment options.

An Orphan Drug Designation was granted to Ridgeback Biotherapeutics, LP, creator the therapy.

Countries across Europe are reinstating travel bans and lockdowns to combat virus.

A new case series report highlights the unique circumstances of infant illness associated with COVID-19.

New data suggests informed, practical pooled testing could improve both public health response and clinical assessment of the pandemic.

Healthcare providers may want to consider these risks when determining which COVID-19 patients could benefit the most from the new monoclonal antibody therapies.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

The CDC stressed that antimicrobial stewardship remains a major public health concern.

The authors note that the difference in hospitalization rate may be partly due to existing immunity to influenza in the population.

Investigators in Tennessee detailed associations between seasonal increases in sporadic pediatric cases of norovirus gastroenteritis and reported norovirus outbreaks among older populations.

Regimen reduces mortality and recovery time in patients severely ill with pneumonia caused by the virus.

At the interim analysis, the mRNA-1273 vaccine was found to have an efficacy of 94.5% against confirmed COVID-19.

Review of data in trial registries shows they specifically excluded this group from studies involving therapies.

Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.

Covaxx CEO Mei Mei Hu has seen vaccines from development all the way through to government approval. She offers her unique perspective into vaccine creation and an update on her company’s COVID-19 vaccine.

Modulating gut microbiota could have therapeutic benefits for people living with HIV, according to a recent study that found HIV infection in women was associated with altered gut microbiota and distinct plasma metabolite profile.

New research finds the rate of psychological distress among US adults remained more than 3 times higher than normal in the early months of the pandemic.

Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development.

UV light-emitting diodes are an emerging technology and a UV source for pathogen inactivation.

In a mature market of agents, the investigational therapy, ibrexafungerp, from Scynexis is looking at a few antifungal indications with a potential FDA approval in 2021.

This non-prescription test allows users to perform and get results themselves without a medical provider or laboratory needed.

Data from three ongoing clinical studies were included in the EUA request.